Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...

A new targeted therapy is significantly improving lung cancer patient outcomes. The drug is called Osimertinib, or brand name ...

Chief of Medical Oncology and Hematology at Mercy Medical Center Dr. David Riseberg joins Jennifer Franciotti to discuss emerging therapies to treat aggressive forms of breast cancer.

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in ...

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients ...